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be prohibited from maintaining, adopting, or enforcing any policy or practice of
linking payments made by VSP to any
VSP panel optometrist to fees charged by
the optometrist to any non-VSP patient or
any non-VSP plan; differentiating its payments to, or other treatment of, any VSP
panel optometrist because the optometrist
charges any fee lower than that charged by
the optometrist to the VSP, to any nonVSP patient, or to any non-VSP plan; taking any action to discourage any VSP panel
optometrist from participating in any nonVSP plan or from offering or charging any
fee lower than that paid to the optometrist
by VSP to any non-VSP patient or to any
non-VSP plan; monitoring or auditing the
fees that any VSP panel optometrist charges
any non-VSP patient or non-VSP plan;
and communicating in any fashion with
any VSP panel optometrist regarding the
his/her participation in any non-VSP plan
or regarding the his/her fees charged to
any non-VSP patient or to any non-VSP
plan. [15:1 CRLR 83-84] At this writing,
the court has not yet approved the proposed consent decree.
In State of Floridav. Johnson & Johnson, et al., No. 94-619-CIV-J-20, the Florida Attorney General filed a nationwide
class action in U.S. District Court for the
Middle District of Florida against Bausch
& Lomb Inc., Johnson & Johnson Vision
Products Inc., the American Optometric
Association, the Contact Lens and Anterior Segment Society, and nine optometrists; the Attorney General contends that
the defendants engaged in a conspiracy
to restrict the sale of soft contact lenses.
According to the action, the defendants
made soft contact lenses available only to
optometrists, ophthalmologists, and opticians-who often mark up the lens prices
significantly-and not to alternative channels of distribution such as pharmacies,
mail-order firms, and similar entities which
may offer discounted prices on the lenses.
The action further claims that the named
optometrists and the Society tried to persuade lens manufacturers not to distribute
soft lenses to alternative chains of distribution, and that the Society threatened not
to prescribe the lenses of any manufacturer which sold its product to pharmacies
or mail-order channels of distribution. At
this writing, the matter is not expected to
be heard until at least late 1996 or early
1997.
*

RECENT MEETINGS
At its March 9-10 meeting, the Board
decided to pursue legislation authorizing
it to conveit its annual license renewal
system to a biennial license renewal system.
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Also at its March meeting, the Board
received testimony in support of and opposition to a proposal to allow optometrists
to use collagen punctal plugs as a diagnostic
tool. Those in support of the proposal testified that it is a quick and progressive procedure; those opposed contended that it is
invasive surgery which exceeds an optometrist's scope of practice. Following discussion, the Board agreed to accept collagen
punctal plugs as a diagnostic tool for optometrists which falls within the scope of practice of optometry. This policy appears to
conflict with the Board's earlier position on
this issue; in May 1991, the Board determined that "the use of collagen implants by
an optometrist would not be within the current scope of optometric practice." [11:3
CRLR 99-100]

*

FUTURE MEETINGS

May 22-23 in San Francisco.
August 24-25 in Sacramento.
December 1-2 in Orange County.

BOARD OF PHARMACY
Executive Officer: PatriciaHarris
(916) 445-5014

p

ursuant to Business and Professions
Code section 4000 et seq., the Board
of Pharmacy grants licenses and permits
to pharmacists, pharmacies, drug manufacturers, wholesalers, medical device retailers, and sellers of hypodermic needles.
It regulates all sales of dangerous drugs,
controlled substances, and poisons. The
Board is authorized to adopt regulations,
which are codified in Division 17, Title 16
of the California Code of Regulations
(CCR). To enforce its regulations, the
Board employs full-time inspectors who
investigate complaints received by the
Board. Investigations may be conducted
openly or covertly as the situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized by
law to suspend or revoke licenses or permits for a variety of reasons, including
professional misconduct and any acts substantially related to the practice of pharmacy.
The Board consists of ten members,
three of whom are nonlicensees. The remaining members are pharmacists, five of
whom must be active practitioners. All are
appointed for four-year terms.
On January 30, Governor Wilson appointed Caleb Zia to the Board as a public
member. Zia is the President and Executive Director of the Minority Business
Council of Orange County, as well as the

President of Chesterfield Corporation, a
business consulting and management firm;
he also serves on the board of Allied Biotechnology International, Inc., a research
and manufacturing company which produces bio-pharmaceuticals, diagnostic assays, and health cire products.
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MAJOR PROJECTS
Medical Device Retailer Locked Storage. AB 1807 (Bronshvag) (Chapter 26,
Statutes of 1994) authorizes a medical device retailer to establish a locked storage
facility for furnishing dangerous devices
in emergencies or after working hours;
provides that the locked storage may be
installed or placed in a service vehicle of
the medical device retailer for after-hours
or emergency delivery to patients who
have prescriptions for dangerous devices;
and authorizes the Board to adopt regulations to permit an exempt person to direct
a non-licensed employee of a medical device retailer who operates a service vehicle equipped with locked storage to deliver a dangerous device from the locked
storage to patients having prescriptions
for dangerous devices. [14:1 CRLR 74]
However, under existing section 1748.1,
Title 16 of the CCR, only an exemptee
(either a California registered pharmacist
or someone who becomes licensed by the
Board as an "exemptee" after passing a
Board-administered exam) may furnish
dangerous devices from a locked storage
of a medical device retailer.
On March 17, the Board published notice of its intent to amend section 1748.1
to implement AB 1807 and expand the personnel authorized to provide emergency
or after-hours delivery of dangerous devices to patients of a medical device retailer to include an employee who operates a service vehicle. The proposed amendments would require that dangerous devices be furnished from the locked storage
only by an exemptee or upon the oral or
written direction of an exemptee to an employee of the medical device retailer who
operates the service vehicle. The amendments further provide that the exemptee is
responsible for checking the contents of
the locked storage and for noting on the
inventory the dangerous devices furnished
within 72 hours of the furnishing of the
dangerous device from the locked storage
to a patient.
At this writing, the Board is scheduled
to hold a public hearing on the proposed
amendments to section 1748.1 on May 24
in Sacramento.
Examination Admission Requirements. Also on March 17, the Board published notice of its intent to amend section
1719, Title 16 of the CCR, which specifies
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the requirements which applicants must
satisfy prior to admission to the pharmacist licensure examination; the existing
regulation requires that all candidates for
the pharmacist licensure examination who
are graduates of a foreign pharmacy school
must demonstrate proficiency in English
by obtaining a score of at least 220 on the
Test of Spoken English (TSE), which is
administered by the Educational Testing
Service (ETS). In October 1994, ETS announced that it will begin administering a
revised TSE that will replace the current
exam in July 1995; the reviewed TSE will
have a very different scoring scale from
the one used for the current exam. To accommodate the new version of the exam, the
proposed amendments would specify that
candidates taking the TSE after June 30,
1995, must achieve a score of at least 50;
candidates taking the TSE before June 30,
1995 must continue to achieve a score of
at least 220. The proposed amendments
would also make technical, nonsubstantive changes.
At this writing, the Board is scheduled
to hold a public hearing on the proposed
amendments to section 1719 on May 24 in
Sacramento.
Revisions to Building and Security
Standards Proposed. On May 15, the
Board published notice of its intent to repeal
sections 1711, 1712, 1713, and adopt new
section 1714, Title 16 of the CCR, to streamline the pharmacy licensure application
process; allow for latitude in the design of
pharmacy facilities; and provide for adequate staff work areas and security in pharmacies by eliminating unnecessarily restrictive building and security standards
and consolidating the existing standards,
with some modifications, into a single regulation. Proposed new section 1714 would
provide that any pharmacy, except hospital inpatient pharmacies, initially licensed
after July 1, 1996, must contain an area
suitable for confidential patient counseling; beginning January 1, 1998, all pharmacies must contain such an area. The
counseling area must be easily accessible
to patient and pharmacist; must not allow
patient access to prescription drugs; and
must be designed to maintain confidentiality and privacy for pharmacist/patient
communication. In evaluating whether an
area is suitable for counseling, the Board
may consider such factors as proximity of
the counseling area to the check-out area;
the volume of pedestrian traffic in and
around the area; the presence of walls or
other barriers; and any evidence that confidential information can be overheard by
others.
The proposed regulation would also
incorporate modified versions of the stan-

dards currently set forth in sections 1711,
1712, and 1713. New section 1714 would
require that each pharmacy licensed by
the Board maintain its facilities, space,
fixtures, and equipment so that drugs are
safely and properly prepared, maintained,
secured, and distributed, and maintain the
pharmacy, fixtures, and equipment in a
clean and orderly condition. The pharmacy shall be of sufficient size to accommodate the safe practice of pharmacy; be
dry, well-ventilated, free from rodents
and insects, and properly lighted; and be
equipped with a sink with hot and cold
running water for pharmaceutical purposes. The proposed regulation would
also specify that each pharmacist, while
on duty, shall be responsible for the security of the prescription department, which
includes having provisions for effective
control against theft or diversion of dangerous drugs and devices orthe records for
such drugs and devices. Possession of a
key to the pharmacy where dangerous
drugs and controlled substances are stored
shall be restricted to a pharmacist. The
proposed regulation would also provide
that an applicant for a licensed premise or
for a renewal of that license must certify
that it meets the requirements of section
1714 at the time of licensure or renewal;
however, the Board may, at its discretion,
waive any provisions of certain specified
sections for good cause shown.
At this writing, the Board is scheduled
to hold a public hearing on the proposed
changes at its July 26 meeting in San
Diego.
Related to the proposed building and
security standards, at its March 29 meeting the Board discussed and agreed to
initiate a pharmacy and wholesaler self-inspection program which would require a
pharmacy or wholesaler licensure applicant to complete a self-inspection form
that covers the building and security standards required when initially applying for
a license and periodically thereafter. In
this way, Board inspectors are not required
to inspect the pharmacy prior to opening,
but may do so shortly thereafter while the
pharmacy is actually operating, thus avoiding delays in opening. The Board noted
that such a program would also serve to
further educate and provide guidance to
pharmacists because the self-inspection
form could be reviewed and discussed
with the pharmacist after the inspector has
conducted the inspection.
Automation of the Triplicate Program. On March 28, the Board's Oversight Committee on the Automation of the
Triplicate Program met to discuss the draft
Feasibility Study Report (FSR) prepared
by the Hawkins Data Center. [15:1 CRLR
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86] The goal of the study was to develop
an automated information system for an
effective statewide method to electronically monitor and track controlled substance prescriptions as an alternative to
the current triplicate system. Through a
detailed analysis, the FSR documents the
problems of the current triplicate system;
sets out the objectives, functional requirements, and costs of implementing an automated electronic monitoring system;
and presents alternatives to such a system.
The recommendation of the FSR is presented in two phases: data collection and
application. The report recommends that
data collection be contracted to an outside
vendor who would collect Schedule II prescription data from pharmacies; the application phase would then involve the development of a new open platform system,
which is a simple data collection system
to record and combine the reported information on one platform. The FSR estimates that the preliminary start-up costs
for the automation project would be $2
million, with maintenance costs of $1.5
million; the maintenance costs for the current triplicate system are $700,000.
After the presentation of the FSR, the
Oversight Committee agreed that the system should be an online, real-time system;
the ultimate goal of the project is to eliminate the triplicate prescription, although
it will be retained for the present; and the
automated system should be evaluated for
effectiveness within three months of implementation so that legislative efforts to
eliminate the triplicate requirement can be
pursued. The Committee also discussed
the costs of implementing and maintaining the automation system; stated that resources currently used for processing and
maintaining triplicate prescriptions could
eventually be redirected to the automation
program; and appointed a subcommittee
to research and pursue funding sources
such as federal grants and private foundations. The Committee also determined that
legislative authority would be required to
implement an electronic monitoring system for controlled substances and discussed proposed language for such legislation.
At its March 29 meeting, the Board
received the Committee's FSR. The Board
expressed its continued support for the
implementation and funding of an automated, real-time electronic monitoring system and agreed to support legislation that
would authorize the implementation of
such a system.
Rulemaking Update. The following
is a status report on Board rulemaking
proposals discussed in previous issues of
the Reporter:
8
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- On February 2, the Office of Administrative Law (OAL) approved the Board's
adoption of new sections 1751.11 and
1751.12, Title 16 of the CCR. Section
1751.11 establishes a list of dangerous
drugs which may be furnished by a pharmacist to a home health agency or licensed
hospice and stored in transportable, tamper-proof, sealed storage containers; it
also creates inventory and recordkeeping
requirements. Section 1751.12 provides
that a pharmacy shall not issue portable
containers unless the home health or licensed hospice complies with the provisions of section 1751.11. [15:1 CRLR 86;
14:4 CRLR 91; 14:2&3 CRLR 95-96]
- At its January 25 meeting, the Board
held a public hearing on the proposed
adoption of new Article 9.5, commencing
with section 1775, to Title 16 of the CCR,
which would establish a citation and fine
program. The regulations would authorize
a Board inspector or committee to issue
citations containing orders of abatement
and/or fines for the unlicensed practice of
pharmacy and for violation of the pharmacist's duty to provide oral consultation
before dispensing medication. The regulations would also set forth the criteria
which must be considered when determining the amount of an administrative fine
(when a fine is assessed with a citation);
provide for the correction of violations
after an order of abatement has been served;
specify the consequences of failing to pay
a fine or comply with an order of abatement; and provide for a process of contesting a citation by appealing to the Board
and requesting an office conference and/or
public hearing. [15:1 CRLR 84; 14:4 CRLR
91-92; 14:2&3 CRLR 95]
At the hearing, the Board received
testimony from the California Retailers
Association (CRA) questioning the necessity of the proposed regulations. CRA's
spokesperson contended that the new program would be unduly burdensome on the
profession; the current system of enforcement is adequate and in fact makes a more
forceful impression on violators and wouldbe violators, as violators now must appear
before the Board's Northern or Southern
Interim Committees (NIC/SIC); the cite
and fine system fails to create uniform and
consistent results because the evaluation
required of inspectors is very subjective;
and the proposed program would result in
undue costs to the Board by establishing
office conferences and could increase the
cost of doing business in California. The
Board responded by explaining that the
implementation of the cite and fine program is an augmentation to the existing
enforcement system, not a substitute; citations and fines may only be issued for
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unlicensed activity and patient consultation violations; and there will be consistency because only the NIC and SIC will
cite and fine pharmacists for violations of
the oral consultation requirement, while
the inspectors will cite and fine only unlicensed activity.
Following the discussion, the Board
adopted the proposed regulations by a vote
of 6-2. The regulations were approved by
the Department of Consumer Affairs (DCA)
on April 17 and the rulemaking file was
submitted on April 21 to OAL, where it is
pending at this writing.
- Also on January 25, the Board held a
public hearing on its proposed amendments
to sections 1749 and 1793.5, and the addition of new section 1749.1, Title 16 of the
CCR, which specify the schedule of fees and
penalties for the licenses, permits, and registrations issued by the Board. The proposed
amendments would increase specified fees
to ensure that the Board's reserve fund is
restored and maintained at a prudent level
for conducting ongoing operations. [15:1
CRLR 85] In late December, the Board
modified the proposed regulatory language
by creating proposed new section 1749.1,
which would set forth the revised fees scheduled to take effect on July 1, 1995, and
released the language for a 15-day comment
period. The Board decided to create new
section 1749.1 to set forth the new fee schedule rather than amend the fee schedule in
section 1749 in order to avoid confusion
about the effective dates of each schedule.
Proposed section 1749.1 would, among other
things, increase the fee for the issuance of a
permit to conduct a pharmacy from $340 to
$400; increase the annual permit renewal fee
from $175 to $250; increase the penalty for
failure to renew from $87.50 to $125; and
increase the fee for the biennial renewal of a
pharmacist's license from $115 to $150. The
amendments to section 1749 would specify
that the current fee schedule remains in effect until June 30, 1995. The amendments to
section 1793.5 would increase the fee for
registration as a pharmacy technician from
$25 to $50.
During the hearing, several witnesses
questioned the need for the fee increase;
the Board expressed its reluctance to increase fees, but stated that if fees are not
increased, the Board will have to cut its
expenses by $1 million in fiscal year
1995-96. The Board also noted that its
fees still tend to be lower than those of
other state boards of pharmacy, and are
substantially lower than those of many
other regulatory boards in California that
govern healing arts professions.
Following discussion, the Board adopted the fee increases and agreed to form a
small committee to identify Board cost re-

quirements, aggressively reduce expenditures, and pursue cost savings. DCA approved the regulations in March and OAL
approved them on April 27.
- On January 25, the Board held a public hearing on its proposed adoption of new
section 1717.4, Title 16 of the CCR, which
would authorize the electronic transmission
of prescriptions by prescribers to pharmacies while ensuring the security and confidentiality of electronically transmitted
prescriptions. As proposed, the regulation
would provide that an electronically transmitted prescription must include the name
and address of the prescriber, a telephone
number for verbal confirmation, date of
transmission, and the identity of the recipient, as well as any other information required by state or federal law. An electronically transmitted prescription shall be
transmitted only to the pharmacy of the
patient's choice; the pharmacy receiving
the electronic transmission must either receive or have the capacity to retrieve the
prescription in hard copy form; and any
hard copy of a prescription shall be maintained on paper of a permanent quality.
The regulation also provides for an interim storage device, which is an electronic file into which a prescription is entered for later retrieval by an authorized
individual; specifies information it shall
record; and requires that the interim storage device be maintained so as to prevent
unauthorized access and use of prescription information. The regulation further
requires that any person who transmits,
maintains, or receives any prescription or
prescription refill orally, in writing, or electronically shall ensure the security, integrity, and confidentiality of the prescription
and any information contained therein.
[15:1 CRLR 85; 14:4 CRLR 89; 14:2&3
CRLR 98]
In response to comments made at the
hearing, the Board added a provision specifying that the prescriber's address and
telephone number for verbal confirmation
may be omitted if they are already on file
in the receiving pharmacy. The Board
agreed that modifying the regulation to
ease the requirement of transmitting this
information each time a prescription is
electronically transmitted would be more
efficient and would save costs. The Board
also added a provision specifying that the
requirement that an electronically transmitted prescription be transmitted only to
the pharmacy of the patient's choice shall
not apply to orders for medications to be
administered in an acute care hospital. The
concern was that the choice of a pharmacy
outside the hospital made by a patient in
an intensive care unit could severely disrupt that patient's care.
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At the conclusion of the hearing, the
Board adopted the modified language of
new section 1717.4. The modified regulation was released for an additional 15-day
comment period in February and approved by DCA in early March. OAL approved the new section on April 19.
- In July 1994, the Board adopted modified amendments to section 1707.2, Title
16 of the CCR, which would apply the
same requirements and standards for oral
consultation to out-of-state pharmacies
which ship, mail, or deliver prescriptions
to California residents as are applied to
in-state pharmacies. However, the Board
postponed administrative approval and
implementation of the amendments in
order to consider further comments and
pursue further discussions with mail-order
pharmacy representatives and the Department of Consumer Affairs, both of whom
disagree with the regulation. [15:1 CRLR
86; 14:4 CRLR 90-91; 14:2&3 CRLR 95]
On February 9, DCA hosted a roundtable discussion of the Board's proposed
amendments. The purpose of the forum
was to provide an opportunity for the exchange of views and ideas between those
who support and oppose the regulation as
applied to out-of-state pharmacies, as well
as to determine if there is any common
ground on how pharmacies that ship, mail,
or deliver prescriptions could provide the
most effective means of consultation. Participants in the forum discussed their concers about the existing and proposed regulations, including the increased costs to
out-of-state pharmacies, the difficulty of
providing consultation, the ability to enforce the regulations, interstate commerce
questions, the need for patient education
and consultation, the need for equal treatment of patients despite the chosen channel of distribution, and the creation of a
competitive advantage or disadvantage
within the industry. Participants also formulated goals for the consultation regulations, discussed possible methodologies
for consultation, and suggested optional
solutions to achieve the goals agreed on.
The forum produced two alternatives to
the proposed regulations. One would require the Board to reevaluate its regulation
as applied to all pharmacies, including
in-state and out-of-state pharmacies, and
adopt a regulatory framework that would
establish the same consultation standard
for all practice settings regardless of where
the prescription is filled or how it is received; consultation would be triggered
by factors established by the Board rather
than the method of delivery. The second
alternative recommends the use of an affirmative check-off box for prescriptions
that are mailed, shipped, or delivered, by

which a patient would indicate by checking a box that he/she wants a pharmacist
to call for consultation.
At its March 30 meeting, the Board
discussed the results of the forum and the
alternative proposals, as well as a University of Southern California (USC)/Kaiser
study currently being conducted which addresses consultation triggered by specific
patient and/or drug criteria. 112:4 CRLR
116] The Board agreed that oral consultation
is important, but members disagreed as to
the best approach; some members wished to
wait until the USC/Kaiser study is completed while others wanted to pursue the
check-off box option. The Board finally
decided by a vote of 5-4 to take no action
on the regulation and to review the final
USC/Kaiser study as well as other studies
about patient consultation. As a result of
this decision, the Board dropped its proposed amendments to section 1707.2, which
had been tabled during these discussions.
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LEGISLATION

SB 988 (Polanco). Existing law provides for the licensure, regulation, and discipline of pharmacists and pharmacies by
the Board; existing law exempts certain
activities, drugs and devices, and facilities
from the application of this law. As amended
April 25, this bill would also exempt the
furnishing of dangerous drugs and devices,
as defined, to recognized schools of nursing,
in certain circumstances. This bill would
also authorize a wholesaler or pharmacy to
furnish dangerous drugs to certain officers
of an ocean vessel in accordance with certain
procedures and federal regulations. [15:1
CRLR 87]
Existing law also sets forth the requirements for licensure as a pharmacist for
applicants who graduate from a foreign
pharmacy school. This bill would revise
those requirements. [15:1 CRLR 86]
SB 988 would also revise requirements
relating to the filing of petitions for reinstatement of a revoked or suspended certificate, or any other license, registration,
permit, or exemption issued by the Board,
and would require the automatic suspension of a pharmacist's certificate if the
pharmacist or other licensee, certificant,
permittee, registrant, or exemptee is incarcerated after conviction of a felony in accordance with specified procedures. [S.
Floor]
AB 611 (Aguiar), as amended May 4,
would create a new licensure program to
be administered by the Board-the veterinary food-animal drug retailer, defined as
a place (other than a pharmacy) that holds
a valid wholesaler certificate, license, permit, or registration, from which veterinary
drugs for food-producing animals are dis-
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pensed pursuant to a prescription from a
veterinarian, and which is issued a permit
for that location by the Board of Pharmacy. The bill would define the term "veterinary food-animal drugs" to include any
drug intended for use in food-producing
animals that, by federal or state law, may
be dispensed only by the prescription of a
licensed veterinarian.
Under AB 611, a veterinary food-animal drug retailer must be placed under the
charge of a responsible person exempt
from the pharmacist registration requirement, who has completed a training program approved by the Board and passed
an examination administered by the Board;
may dispense veterinary food-animal drugs
for food-producing animals under specified
conditions; and may dispense veterinary
food-animal drugs only to another veterinary food-animal drug retailer, a pharmacy,
a veterinarian, or to a veterinarian's client
pursuant to a veterinarian's prescription.
AB 611 is nearly identical to AB 2973
(Aguiar), which was vetoed in September
1994 by Governor Wilson, who claimed
that the fees charged were not sufficient to
make the regulatory program self-supporting. [14:4 CRLR 92] The author and the
sponsor, the California Veterinary Medical
Association, claim that the Department of
Finance cost estimate of $ 100,000 annually
for the program was erroneous, and that it
will cost only $20,000 annually. [S. Floor]
AB 1107 (Campbell). Under existing
law, the right to sell or furnish prescription
lenses is limited exclusively to licensed
physicians, optometrists, and registered
dispensing opticians. As amended May
15, this bill would, notwithstanding that
limitation, authorize a pharmacist to dispense replacement contact lenses, as defined in accordance with certain requirements.
Existing law requires nonresident pharmacies, as defined, to register with the
Board and to disclose certain information
to the Board. This bill would instead require that nonresident pharmacies comply
with certain requirements, maintain certain records, and disclose certain information to the Board. This bill would also add
a requirement that those pharmacies maintain records of all replacement contact lenses
shipped, mailed, or delivered to California
residents. [A. Appr]
AB 1163 (V. Brown). Existing law
provides for the licensure and regulation
of pharmacists and provides that a violation of the provisions regulating the practice of pharmacy is subject to criminal
sanction. Existing law also provides that a
registered nurse who is authorized by administrative regulations and is employed
by or serves as a consultant for a licensed
9
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skilled nursing, intermediate care or other
health care facility, may orally or electronically transmit to the furnisher a prescription lawfully ordered by a person authorized to prescribe drugs or devices, and
requires the furnisher to record the name
of the person who transmits the order. As
introduced February 23, this bill would
similarly permit a registered nurse who is
employed by a home health agency to
orally transmit a prescription, and require
the furnisher to record the name of the
person who transmits the order. [A. Floor]
AB 1529 (Vasconcellos). Existing law
generally prohibits the possession of marijuana or concentrated cannabis and prohibits the planting, cultivating, harvesting,
drying, or processing of marijuana. As
amended May 9, this bill would provide
that these prohibitions do not apply to any
person who possesses marijuana or plants,
cultivates, harvests, dries, or processes
marijuana for his/her own personal medicinal use or for the personal medicinal use
of another for whom the person is the legal
guardian or caregiver, where the medicinal use has been approved in writing by a
licensed physician for the treatment of
AIDS, cancer, glaucoma, or multiple sclerosis. [S. Floor]
AB 1136 (V. Brown). Existing law
imposes various requirements on health
care service plans and insurers, and permits those plans and insurers to enter into
various contracts with health care providers. As amended April 17, this bill would
provide that the offer or delivery by any
health care service plan or insurer, or the
receipt or acceptance by any pharmacist,
of any rebate, refund, commission, preference, patronage, dividend, discount, or
other consideration as compensation or
inducement for substituting drugs is unlawful. [A. Appr]
AB 322 (Alpert). Existing law categorizes controlled substances into five schedules and places the greatest restrictions on
those contained in Schedule I. Existing law
provides that while only the controlled
substances in Schedules II through V may
be prescribed, the controlled substances in
Schedule II may be prescribed only pursuant to a triplicate prescription, as specified. As introduced February 9, this bill
would transfer the controlled substance
methylphenidate from Schedule II to Schedule III. [A. PubS]
SB 641 (Craven). Existing law authorizes a licensed pharmacist to dispense drugs upon a transmittal order of
a physician assistant (PA) who has been
delegated that authority by a physician.
As introduced February 22, this bill would
state the intent of the Legislature to enact
guidelines for pharmacists who accept
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Schedule II prescriptions from PAs in accordance with those provisions. [S. B&P]
SB 922 (Mello). Existing law requires
the Board to adopt regulations that apply
the same requirements or standards for
oral consultation to certain out-of-state
pharmacies that are applied to certain instate pharmacies, and provides that the
regulations shall not result in any unnecessary delay in patients receiving their
medication. As introduced February 23,
this bill would additionally provide that
the regulations shall also not result in any
unnecessary expense to patients receiving
their medication. [S. B&P]
SB 959 (Mello), as introduced February 23, would state the intent of the legislature that pharmacists be prohibited from
receiving compensation for the dispensing
of prescription drugs beyond a predetermined dispensing fee established by the
patient's insurance carrier. [S. Rls]
SB 777 (Polanco). Existing law provides for the licensure and discipline of
psychologists administered by the Board
of Psychology (BOP), and defines the
practice of psychology. Existing law excludes from the practice of psychology the
prescribing of drugs, the performance of
surgery, and the administration of electroconvulsive therapy. As amended May 2,
this bill would require BOP to establish
and administer a certification program to
grant licensed psychologists prescriptive
authority, as defined, and to develop procedures for that certification with the advice of the state Department of Health
Services and the Board of Pharmacy. The
bill would require each applicant for certification to satisfy certain educational and
training requirements. This bill would also
delete the exclusion of the prescribing of
drugs by certified psychologists from the
practice of psychology. [S. B&P]
SB 510 (Maddy), as amended May 2,
would authorize optometrists to use specified diagnostic drugs and to prescribe specified therapeutic pharmaceutical agents
(TPAs) incidental to their practice of optometry (excluding controlled substances).
Currently, California optometrists have
no prescriptive authority. This bill would
make it a misdemeanor for any optometrist to refer a patient to a pharmacy that is
owned by the optometrist or in which the
optometrist has a proprietary interest (see
agency report on BOARD OF OPTOMETRY for a detailed discussion of this bill).
[S. B&PI
AB 1969 (Isenberg), as amended April
5, is substantially similar to SB 510 above;
however, instead of providing that any
use, prescribing, or dispensing of TPAs to
a patient by an optometrist is limited to
that which is incidental to the practice of

optometry, AB 1969 would require that
such use, prescribing, or dispensing of a
pharmaceutical agent be limited only to
the practice of optometry. [A. Health]
AB 1572 (Allen), as amended May 2,
would, among other things, repeal the existing Pharmacy Law and reenact it as
revised as reorganized. The purpose of the
bill is not to change any substantive provision of existing pharmacy law, but to
recast it into a more organized format and
to eliminate duplication and archaic language. This bill is sponsored by the Board
of Pharmacy and is the product of several
years of work by the Pharmacy Law Committee. [A. Health]

U

RECENT MEETINGS
At its January 25 meeting, the Board
adopted draft scope of practice guidelines in order to implement SB 1759
(Chapter 1161, Statutes of 1994), which
became effective on January 1, 1995,
and authorizes pharmacists to perform
expanded functions in a variety of settings including unlicensed facilities operated by a health care service plan, a
licensed clinic, or a provider who contracts with a licensed health care service
plan. [14:4 CRLR 92] A pharmacist may
now order or perform routine drug therapy-related patient assessment procedures
including temperature, pulse, and respiration; order drug therapy laboratory tests;
administer drugs by injection pursuant
to a prescriber's order; and adjust the
drug regimen of a patient pursuant to a
written specific order by the patient's
prescriber. Pharmacists are authorized
to perform these expanded functions in
accordance with the policies, procedures,
or protocols of the facility, licensed clinic,
or health care service plan. The Board's
guidelines were drafted to aid in the
development of those policies, procedures, or protocols, which are not subject to prior approval by the Board. The
guidelines state that the procedures must
be in writing, dated, and signed by the
personnel authorized to approve it; specify which functions the pharmacist may
perform and under what circumstances;
state any specific requirements to be followed by the pharmacist in performing
those functions; and specify any experience, education, or training requirements
for performance of those functions. The
procedures must also establish a method
for initial and continuing evaluation of
the competence of the pharmacists authorized to perform those functions;
specify the scope of supervision required;
state the limitations on settings, if any,
in which the functions may be performed;
set forth any specialized circumstances
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under which the pharmacist is to immediately communicate with a patient's physician; provide for a method of periodic
review of the functions performed by
pharmacists; and describe the method
used in developing and approving the
procedures. The draft guidelines also include example formats adopted from existing standardized procedures to be used
as a guide in developing the procedures
for the expanded functions pharmacists
may perform.
At the Board's March 29 meeting,
the Board discussed the development
and implementation of its proposed "Ask
Your Pharmacist" public education program which would inform consumers
about the benefits of the new oral consultation requirement, among other things.
[15:1 CRLR 87; 14:4 CRLR 94] With
the help of DCA's public affairs unit, the
Board staff developed a logo and the
slogan "Be Aware & Take Care: Talk to
Your Pharmacist!" Several designs incorporating the logo and slogan for a
brochure were submitted to the Board
for consideration; the Board agreed on a
design and went on to discuss three- and
six-month plans for implementing the
public education program. The threemonth plan involves incorporating the
logo on all printed material, developing
a Board pamphlet and series of fact sheets,
developing new signage for pharmacies,
and beginning discussions with drug
companies regarding partnering activities with respect to funding and marketing assistance. The plan for the subsequent six months includes printing and
distributing the Board pamphlet and fact
sheets, sending new signage to pharmacies for posting, developing events for
awareness month, and continuing to work
with drug companies on funding and marketing. The Board also discussed sources
of funding and methods of distribution.
It was determined that the cost of printing brochures will be minimal and the
brochures could be distributed with consumer complaint forms, sent to legislators, and distributed to consumer groups
as well as interested parties in the profession. The Board agreed to proceed
with the three- and six-month plang, although it removed from those plans a
proposal to issue press releases on disciplinary activity and the development
of investigative stories for the media so
as to maintain a positive focus for the
program.
E FUTURE MEETINGS
May 24-25 in Sacramento.
July 26-27 in San Diego.
October 25-26 in San Francisco.

BOARD OF
REGISTRATION FOR
PROFESSIONAL
ENGINEERS AND
LAND SURVEYORS
Executive Officer:
Harold L. Turner
(916) 263-2222
he Board of Registration for Professional Engineers and Land Surveyors
(PELS) regulates the practice of engineering
and land surveying through its administration of the Professional Engineers Act,
sections 6700 through 6799 of the Business
and Professions Code, and the Professional
Land Surveyors Act, sections 8700 through
8806 of the Business and Professions Code.
The Board's regulations are found in Division 5, Title 16 of the California Code of
Regulations (CCR), sections 400 through
471.
The basic functions of the Board are to
conduct examinations, issue certificates,
registrations, and/or licenses, and appropriately channel complaints against registrants/licensees. The Board is additionally
empowered to suspend or revoke registrations/licenses. The Board considers the
proposed decisions of administrative law
judges who hear appeals of applicants who
are denied a registration/license, and those
who have had their registration/license suspended or revoked for violations.
Professional engineers are registered
through the three Practice Act categories
of civil, electrical, and mechanical engineering under section 6730 of the Business and Professions Code. Land surveyors, another Practice Act category, are registered through section 8725 of the Business and Professions Code. The Title Act
categories of agricultural, chemical, control system, corrosion, fire protection, industrial, manufacturing, metallurgical, nuclear, petroleum, quality, safety, and traffic engineering are registered under section 6732 of the Business and Professions
Code.
Structural engineering and geotechnical engineering are "title authorities" linked
to the civil Practice Act and require an
additional examination after qualification
as a civil engineer.
The Board consists of thirteen members: seven public members, one licensed
land surveyor, four registered Practice Act
engineers and one Title Act engineer. The
Governor appoints eleven of the members
for four-year terms that expire on a staggered basis. Additionally, both the Assembly Speaker and the Senate Rules Committee appoint one public member each.
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The Board has established four standing committees and appoints other special
committees as needed. The four standing
committees are Administration, Enforcement, Examination/Qualifications, and
Legislation. Committees function in an
advisory capacity unless specifically authorized by the Board to make binding
decisions.
PELS is subject to a "sunset" provision.
Section 8710 Business and Professions
Code, which vests power in the Board, will
"become inoperative on July 1, 1998, and,
as of January 1, 1999, is repealed, unless a
later enacted statute, which becomes effective on or before January 1, 1999 deletes or
extends the dates on which it becomes inoperative and is repealed."

U

MAJOR PROJECTS

Professional Engineers Act Rewrite
Goes to Public Forum. PELS is currently
in the midst of a comprehensive review of
the Professional Engineers (PE) Act, its
regulations, and the way the state of California licenses and classifies various engineering disciplines; this effort has resulted
largely from November 1993 criticism by
the Center for Public Interest Law (CPIL)
that PELS' engineering statutes and regulations are extremely vague and in need
of major restructuring and modernization,
and former Board President Rich Johnson's
"white paper" entitled Confronting the Issues of EngineeringDiscipline Definitions,
in which Johnson agreed with CPIL that
the Board's statutes are internally inconsistent and lack clarity. [14:4 CRLR 95;
14:2&3 CRLR 99; 14:1 CRLR 77]
At its September 1994 meeting, PELS
announced that it had hired attorney/civil
engineer Jimmie Wing to assist in developing legislative language for the rewrite;
Wing filled the Board's Staff Counsel III
vacancy. [15:1 CRLR 88] According to
State Personnel Board specifications, one
distinguishing characteristic of the Staff
Counsel III position is that the person is
"expected to be [an] expert in the most
complex area of the law within the departmental legal program"; additionally, the
specification states that "[aipplicants must
have active membership in the State Bar
before they will be eligible for appointment." State Bar records show that Wing's
State Bar license was on inactive status
from July 1, 1994 until January 1995; however, in January Wing's status was returned to active status.
At its February 10, March 17, and April
28 meetings, the Board reviewed regulatory schemes used in other states, discussed existing problems with the PE Act,
and developed a conceptual outline of the
rewrite. Significantly, the Board wants to
9

